[1] Nensa F, Bamberg F, Rischpler C, et al.  Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM)[J]. Eur Radiol, 2018, 28(10): 4086-4101.   doi: 10.1007/s00330-017-5008-4
[2] Krizsan AK, Lajtos I, Dahlbom M, et al.  A promising future: comparable imaging capability of MRI-compatible silicon photomultiplier and conventional photosensor preclinical PET systems[J]. J Nucl Med, 2015, 56(12): 1948-1953.   doi: 10.2967/jnumed.115.157677
[3] Delso G, Martinez-Möller A, Bundschuh RA, et al.  Evaluation of the attenuation properties of MR equipment for its use in a whole-body PET/MR scanner[J]. Phys Med Biol, 2010, 55(15): 4361-4374.   doi: 10.1088/0031-9155/55/15/011
[4] Eiber M, Martinez-Möller A, Souvatzoglou M, et al.  Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions[J]. Eur J Nucl Med Mol Imaging, 2011, 38(9): 1691-1701.   doi: 10.1007/s00259-011-1842-9
[5] Schulz V, Torres-Espallardo I, Renisch S, et al.  Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data[J]. Eur J Nucl Med Mol Imaging, 2011, 38(1): 138-152.   doi: 10.1007/s00259-010-1603-1
[6] Lois C, Bezrukov I, Schmidt H, et al.  Effect of MR contrast agents on quantitative accuracy of PET in combined whole-body PET/MR imaging[J]. Eur J Nucl Med Mol Imaging, 2012, 39(11): 1756-1766.   doi: 10.1007/s00259-012-2190-0
[7] Lau JMC, Laforest R, Sotoudeh H, et al.  Evaluation of attenuation correction in cardiac PET using PET/MR[J]. J Nucl Cardiol, 2017, 24(3): 839-846.   doi: 10.1007/s12350-015-0197-1
[8] Kolbitsch C, Ahlman MA, Davies-Venn C, et al.  Cardiac and respiratory motion correction for simultaneous cardiac PET/MR[J]. J Nucl Med, 2017, 58(5): 846-852.   doi: 10.2967/jnumed.115.171728
[9] Ouyang J, Li QZ, Georges EF.  Magnetic resonance-based motion correction for positron emission tomography imaging[J]. Semin Nucl Med, 2013, 43(1): 60-67.   doi: 10.1053/j.semnuclmed.2012.08.007
[10] Fürst S, Grimm R, Hong I, et al.  Motion correction strategies for integrated PET/MR[J]. J Nucl Med, 2015, 56(2): 261-269.   doi: 10.2967/jnumed.114.146787
[11]

Guo R, Petibon Y, Ma YX, et al. MR-based motion correction for cardiac PET parametric imaging: a simulation study[J/OL]. EJNMMI Phys, 2018, 5(1): 3[2019-04-21]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792384/. DOI: 10.1186/s40658-017-0200-9.
[12] 刘家金, 陈英茂, 张雄伟, 等.  PET/MR一体机操作优化的初步经验[J]. 中华核医学与分子影像杂志, 2014, 34(6): 438-442.   doi: 10.3760/cma.j.issn.2095-2848.2014.06.005
Liu JJ, Chen YM, Zhang XW, et al.  Initial experience on protocol optimization for integrated PET/MR[J]. Chin J Nucl Med Mol Imaging, 2014, 34(6): 438-442.   doi: 10.3760/cma.j.issn.2095-2848.2014.06.005
[13] Robson PM, Dey D, Newby DE, et al.  MR/PET imaging of the cardiovascular system[J]. JACC Cardiovascular Imaging, 2017, 10(10): 1165-1179.   doi: 10.1016/j.jcmg.2017.07.008
[14] Tu CQ, Thomas SCN, Russell EJ, et al.  Multimodality PET/MRI agents targeted to activated macrophages[J]. J Biol Inorg Chem, 2014, 19(2): 247-258.   doi: 10.1007/s00775-013-1054-9
[15] Hundley WG, Bluemke DA, Finn JP, et al.  ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on expert consensus documents[J]. J Am Coll Cardiol, 2010, 55(23): 2614-2662.   doi: 10.1016/j.jacc.2009.11.011
[16] Xie YB, Kim YJ, Pang J, et al.  Coronary atherosclerosis T1-weighed characterization with integrated anatomical reference: comparison with high-risk plaque features detected by invasive coronary imaging[J]. JACC Cardiovasc Imaging, 2017, 10(6): 637-648.   doi: 10.1016/j.jcmg.2016.06.014
[17] 彭琨, 李剑明.  PET/CT冠状动脉血流储备测定在冠状动脉微血管性疾病中的研究进展[J]. 国际放射医学核医学杂志, 2018, 42(5): 436-440.   doi: 10.3760/cma.j.issn.1673-4114.2018.05.009
Peng K, Li JM.  Progress in the measurement of coronary reverse flow in coronary microvascular diseaseswith PET/CT[J]. Int J Radiat Med Nucl Med, 2018, 42(5): 436-440.   doi: 10.3760/cma.j.issn.1673-4114.2018.05.009
[18] Sciagrà R, Passeri A, Bucerius J, et al.  Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM)[J]. Eur J Nucl Med Mol Imaging, 2016, 43(8): 1530-1545.   doi: 10.1007/s00259-016-3317-5
[19] Rischpler C, Nekolla SG, Dregely I, et al.  Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects[J]. J Nucl Med, 2013, 54(3): 402-415.   doi: 10.2967/jnumed.112.105353
[20] Bulluck H, White SK, Fröhlich GM, et al.  Quantifying the area-at-risk in reperfused STEMI patients using hybrid cardiac PET-MR imaging[J]. Circ Cardiovasc Imaging, 2016, 9(3): e003900-.   doi: 10.1161/CIRCIMAGING.115.003900
[21] Rischpler C, Langwieser N, Souvatzoglou M, et al.  PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake[J]. Eur Heart J Cardiovasc Imaging, 2015, 16(6): 661-669.   doi: 10.1093/ehjci/jeu317
[22] Lurz P, Luecke C, Eitel I, et al.  Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-Trial[J]. J Am Coll Cardiol, 2016, 67(15): 1800-1811.   doi: 10.1016/j.jacc.2016.02.013
[23]

Wu CX, Li F, Niu G, et al. PET imaging of inflammation biomarkers[J/OL]. Theranostics, 2013, 3(7): 448-466[2019-04-21]. https://www.ncbi.nlm.nih.gov/pmc/journals/1512/. DOI: 10.7150/thno.6592.
[24] Nensa F, Kloth J, Tezgah E, et al.  Feasibility of FDG-PET in myocarditis: Comparison to CMR using integrated PET/MRI[J]. J Nucl Cardiol, 2018, 25(3): 785-794.   doi: 10.1007/s12350-016-0616-y
[25] Abgral R, Dweck MR, Trivieri MG, et al.  Clinical utility of combined FDG-PET/MR to assess myocardial disease[J]. JACC Cardiovasc Imging, 2017, 10(5): 594-597.   doi: 10.1016/j.jcmg.2016.02.029
[26] Schatka I, Bengel FM.  Advanced imaging of cardiac sarcoidosis[J]. J Nucl Med, 2014, 55(1): 99-106.   doi: 10.2967/jnumed.112.115121
[27] Nensa F, Tezgah E, Poeppel T, et al.  Diagnosis and treatment response evaluation of cardiac sarcoidosis using positron emission tomography/magnetic resonance imaging[J]. Eur Heart J, 2015, 36(9): 550-.   doi: 10.1093/eurheartj/ehu473
[28] Fontana M, Chung R, Hawkins PN, et al.  Cardiovascular magnetic resonance for amyloidosis[J]. Heart Fail Rev, 2015, 20(2): 133-144.   doi: 10.1007/s10741-014-9470-7
[29] Barison A, Aquaro GD, Pugliese NR, et al.  Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging[J]. J Intern Med, 2015, 277(5): 605-614.   doi: 10.1111/joim.12324
[30] Trivieri MG, Dweck MR, Abgral R, et al.  18F-Sodium fluoride PET/MR for the assessment of cardiac amyloidosis[J]. J Am Coll Cardiol, 2016, 68(24): 2712-2714.   doi: 10.1016/j.jacc.2016.09.953
[31] Lee SP, Lee ES, Choi H, et al.  11C-Pittsburgh B PET imaging in cardiac amyloidosis[J]. JACC Cardiovasc Imaging, 2014, 8(1): 50-59.   doi: 10.1016/j.jcmg.2014.09.018
[32]

Pilebro B, Lindqvist P, Gustafsson S, et al. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) detects amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)[J/OL]. Orphanet J Rare Dis, 2015, 10. https://link.springer.com/article/10.1186/1750-1172-10-S1-O15#citeas. DOI: 10.1186/1750-1172-10-S1-O15.
[33] Xie YB, Jin H, Zeng MS, et al.  Coronary artery plaque imaging[J]. Curr Atheroscler Rep, 2017, 19(9): 37-.   doi: 10.1007/s11883-017-0672-z
[34] Joshi NV, Vesey AT, Williams MC, et al.  18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial[J]. Lancet, 2014, 383(9918): 705-713.   doi: 10.1016/S0140-6736(13)61754-7
[35] Lau JMC, Laforest R, Nensa F, et al.  Cardiac applications of PET/MR imaging[J]. Magn Reson Imaging Clin N Am, 2017, 25(2): 325-333.   doi: 10.1016/j.mric.2016.12.007
[36] Nensa F, Tezgah E, Poeppel TD, et al.  Integrated 18F-FDG PET/MR imaging in the assessment of cardiac masses: a pilot study[J]. J Nucl Med, 2014, 56(2): 255-260.   doi: 10.2967/jnumed.114.147744